Trial Profile
Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 25 May 2017 New trial record